Log in to save to my catalogue

Use of [ 18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with...

Use of [ 18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751228504

Use of [ 18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [ 18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

About this item

Full title

Use of [ 18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [ 18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2014-12, Vol.15 (13), p.1493-1502

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundAn effective and well tolerated treatment is needed for patients with early HER2-positive breast cancer who do not achieve a pathological complete response after neoadjuvant therapy. The AVATAXHER trial aimed to predict pathological complete response early with the use of PET and to investigate whether the addition of bevacizumab c...

Alternative Titles

Full title

Use of [ 18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [ 18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1751228504

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751228504

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(14)70475-9

How to access this item